Cargando…

One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient

BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV. METHODS: This was a prospective, single-...

Descripción completa

Detalles Bibliográficos
Autores principales: Choo, Hun Gu, Lee, Jin Hae, Oh, Hyun Sub, Kim, Soon Hyun, You, Yong Sung, Kwon, Oh Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890830/
https://www.ncbi.nlm.nih.gov/pubmed/33602156
http://dx.doi.org/10.1186/s12886-021-01829-2
_version_ 1783652577073692672
author Choo, Hun Gu
Lee, Jin Hae
Oh, Hyun Sub
Kim, Soon Hyun
You, Yong Sung
Kwon, Oh Woong
author_facet Choo, Hun Gu
Lee, Jin Hae
Oh, Hyun Sub
Kim, Soon Hyun
You, Yong Sung
Kwon, Oh Woong
author_sort Choo, Hun Gu
collection PubMed
description BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV. METHODS: This was a prospective, single-arm, interventional case series study of 25 PCV patients; 12 pre-treated and 13 treatment-naïve patients. The patients were treated and monitored for 12 months. Each patient was administered with an aflibercept (2.0 mg) injection every month for the first 3 months (the loading phase), and thereafter, once every 2 months. At every follow-up visit, best-corrected visual acuity (BCVA) test, fundus examination, and optical coherence tomography for measuring the central subfield macular thickness (CSMT) were performed. Fluorescein and indocyanine green angiography were conducted at baseline and at 4 and 12 months. RESULTS: After 12 months of aflibercept therapy, the mean BCVA of the patients significantly improved from 65.48 letters at baseline to 69.91 letters (p=0.001), and the CSMT significantly decreased from 406.92 um at baseline to 276.12 um (p< 0.001). Additionally, ten patients (40%) showed complete polyp regression. The treatment-naïve patients showed a statistically significant improvement in BCVA from 66.58 letters at baseline to 76.36 letters at 12 months, and a significant decrease in CSMT, from 462 to 243 um. In the pre-treated group, there was no change in BCVA (64.46 letters), and the decrease in CSMT from 356.08 to 303.69 um was not statistically significant. CONCLUSIONS: The fixed-dosing aflibercept regimen is effective for treating patients with PCV and is more effective in treatment-naïve patients than in pre-treated patients. TRIAL REGISTRATION: Clinical Research Information Service (CRiS), Republic of Korea. Identifer: KCT0005798, Registered: Jan 20, 2021. Retrospectively registered, URL: https://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=18546
format Online
Article
Text
id pubmed-7890830
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78908302021-02-22 One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient Choo, Hun Gu Lee, Jin Hae Oh, Hyun Sub Kim, Soon Hyun You, Yong Sung Kwon, Oh Woong BMC Ophthalmol Research Article BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV. METHODS: This was a prospective, single-arm, interventional case series study of 25 PCV patients; 12 pre-treated and 13 treatment-naïve patients. The patients were treated and monitored for 12 months. Each patient was administered with an aflibercept (2.0 mg) injection every month for the first 3 months (the loading phase), and thereafter, once every 2 months. At every follow-up visit, best-corrected visual acuity (BCVA) test, fundus examination, and optical coherence tomography for measuring the central subfield macular thickness (CSMT) were performed. Fluorescein and indocyanine green angiography were conducted at baseline and at 4 and 12 months. RESULTS: After 12 months of aflibercept therapy, the mean BCVA of the patients significantly improved from 65.48 letters at baseline to 69.91 letters (p=0.001), and the CSMT significantly decreased from 406.92 um at baseline to 276.12 um (p< 0.001). Additionally, ten patients (40%) showed complete polyp regression. The treatment-naïve patients showed a statistically significant improvement in BCVA from 66.58 letters at baseline to 76.36 letters at 12 months, and a significant decrease in CSMT, from 462 to 243 um. In the pre-treated group, there was no change in BCVA (64.46 letters), and the decrease in CSMT from 356.08 to 303.69 um was not statistically significant. CONCLUSIONS: The fixed-dosing aflibercept regimen is effective for treating patients with PCV and is more effective in treatment-naïve patients than in pre-treated patients. TRIAL REGISTRATION: Clinical Research Information Service (CRiS), Republic of Korea. Identifer: KCT0005798, Registered: Jan 20, 2021. Retrospectively registered, URL: https://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=18546 BioMed Central 2021-02-18 /pmc/articles/PMC7890830/ /pubmed/33602156 http://dx.doi.org/10.1186/s12886-021-01829-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Choo, Hun Gu
Lee, Jin Hae
Oh, Hyun Sub
Kim, Soon Hyun
You, Yong Sung
Kwon, Oh Woong
One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
title One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
title_full One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
title_fullStr One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
title_full_unstemmed One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
title_short One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
title_sort one-year outcomes of fixed-dosing aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890830/
https://www.ncbi.nlm.nih.gov/pubmed/33602156
http://dx.doi.org/10.1186/s12886-021-01829-2
work_keys_str_mv AT choohungu oneyearoutcomesoffixeddosingaflibercepttherapyforpretreatedandnaivepolypoidalchoroidalvasculopathypatient
AT leejinhae oneyearoutcomesoffixeddosingaflibercepttherapyforpretreatedandnaivepolypoidalchoroidalvasculopathypatient
AT ohhyunsub oneyearoutcomesoffixeddosingaflibercepttherapyforpretreatedandnaivepolypoidalchoroidalvasculopathypatient
AT kimsoonhyun oneyearoutcomesoffixeddosingaflibercepttherapyforpretreatedandnaivepolypoidalchoroidalvasculopathypatient
AT youyongsung oneyearoutcomesoffixeddosingaflibercepttherapyforpretreatedandnaivepolypoidalchoroidalvasculopathypatient
AT kwonohwoong oneyearoutcomesoffixeddosingaflibercepttherapyforpretreatedandnaivepolypoidalchoroidalvasculopathypatient